Literature DB >> 1847133

Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding.

C G Unson1, D Macdonald, K Ray, T L Durrah, R B Merrifield.   

Abstract

Recent studies on the glucagon antagonist des-His1-[Glu9]glucagon amide have resulted in pure inhibitors of the hormone, suggesting that the inhibitory properties may be centered around position 9. The present study was designed to investigate the chemical characteristics of substitutions in position 9 of glucagon that determine binding affinity and biological activity. Twenty replacement analogs of position 9 of glucagon were synthesized and assessed for their ability to bind to the glucagon receptor in rat hepatocyte membranes and to activate adenylate cyclase. Any substitution of aspartic acid 9 was accompanied by a severely diminished capacity to transmit the biological signal, while retaining receptor binding affinity. These results are an indication of an uncoupling of receptor binding and biological activity at this locus and define a central role of aspartic acid 9 in glucagon activity. Single replacement or deletion of either His1 or Asp9 in glucagon caused a 20- to 50-fold decrease in cyclase activity, whereas these same changes made in tandem caused virtually complete loss of activity, with decreases of 10(4)-to 10(6)-fold. These observations have led us to speculate that, at the molecular level, the region of glucagon required for transduction of the biological response may be distinct from the binding region and is mediated by a coupled interaction between His1 and Asp9 of the hormone and a complementary functional site of the glucagon receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847133

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system.

Authors:  S R Post; P G Rubinstein; H S Tager
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

2.  A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells.

Authors:  M Rusnati; P Dell'Era; C Urbinati; E Tanghetti; M L Massardi; Y Nagamine; E Monti; M Presta
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

3.  Structural transitions and interactions in the early stages of human glucagon amyloid fibrillation.

Authors:  Balakrishnan S Moorthy; Hamed Tabatabaei Ghomi; Markus A Lill; Elizabeth M Topp
Journal:  Biophys J       Date:  2015-02-17       Impact factor: 4.033

4.  Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.

Authors:  Jason Perret; Mélanie Van Craenenbroeck; Ingrid Langer; Pascale Vertongen; Françoise Gregoire; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

5.  Glucagon treatment interferes with an early step of duck hepatitis B virus infection.

Authors:  M Hild; O Weber; H Schaller
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.

Authors:  S Runge; B S Wulff; K Madsen; H Bräuner-Osborne; L B Knudsen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

7.  The serendipitous origin of chordate secretin peptide family members.

Authors:  João C R Cardoso; Florbela A Vieira; Ana S Gomes; Deborah M Power
Journal:  BMC Evol Biol       Date:  2010-05-06       Impact factor: 3.260

8.  Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding.

Authors:  C G Unson; A M Cypess; C R Wu; P K Goldsmith; R B Merrifield; T P Sakmar
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Identification of the guanine binding domain peptide of the GTP-binding site of glucagon.

Authors:  M Shoemaker; P C Lin; B Haley
Journal:  Protein Sci       Date:  1992-07       Impact factor: 6.725

Review 10.  Proglucagon-Derived Peptides as Therapeutics.

Authors:  Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.